Inflammatory Bowel Disease Is Associated With an Increased Risk of End‐Stage Renal Disease: A Population‐Based Cohort Study
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70845 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Onuma Sattayalertyanyong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bingham Chair in Gastroenterology.
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD) is associated with renal complications, but population‐based data on end‐stage renal disease (ESRD) are limited.
Aim
To evaluate the incidence of ESRD and renal transplantation in IBD compared with the general population and to identify predictive factors associated with ESRD in the IBD population.
Methods
This was a retrospective population‐based cohort study using the University of Manitoba IBD Epidemiology Database linked to administrative healthcare data from 1984 to 2023 (12,639 IBD patients matched with 126,180 controls). ESRD was defined as requiring any two claims for outpatient dialysis within a 1‐year period. Predictive factors were identified using proportional hazard regression and nested case–control logistic regression analyses.
Results
IBD patients had a significantly higher incidence of dialysis (1.48% vs. 0.82%, p < 0.0001) and kidney transplantation (0.25% vs. 0.10%, p < 0.0001) than controls. IBD was an independent predictor of ESRD (HR = 1.53, 95% CI 1.23–1.90), with stronger associations in CD (HR = 1.93, 95% CI 1.39–2.68) than UC (HR = 1.28, 95% CI 0.96–1.72). Traditional risk factors including diabetes (HR = 3.82, 95% CI 3.22–4.53), hypertension (HR = 1.91, 95% CI 1.58–2.30), and congestive heart failure (HR = 6.37, 95% CI 5.25–7.72) remained strongly predictive. Within the IBD population, oral steroid treatment (OR = 2.0, 95% CI 1.06–3.81), allopurinol use (OR = 4.06, 95% CI 1.49–11.1) and bowel surgery (OR = 2.77, 95% CI 1.51–5.09) significantly predicted dialysis initiation.
Conclusions
Persons with IBD have an increased risk of ESRD by nearly 50%, with CD showing a greater risk than UC. Bowel surgery, allopurinol use and oral steroid therapy are important predictors, emphasising the necessity of careful renal monitoring in IBD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.
- Department of Medicine, Rady Faculty of Health Sciences, Max Rady College of Medicine, Winnipeg, Manitoba, Canada.
ORCID-Profile: Charles N Bernstein
Förderung
- Bingham Chair in Gastroenterology
Zitieren
APA
Sattayalertyanyong, O., Nugent, Z., Barr, B., Bernstein, K. N., & Bernstein, C. N. (2026). Inflammatory Bowel Disease Is Associated With an Increased Risk of End‐Stage Renal Disease: A Population‐Based Cohort Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70845
Vancouver
Sattayalertyanyong O, Nugent Z, Barr B, Bernstein KN, Bernstein CN. Inflammatory Bowel Disease Is Associated With an Increased Risk of End‐Stage Renal Disease: A Population‐Based Cohort Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70845
BibTeX
@article{Sattayalertyanyong2026,
author = {Sattayalertyanyong, Onuma and Nugent, Zoann and Barr, Bryce and Bernstein, Keevin N and Bernstein, Charles N},
title = {Inflammatory Bowel Disease Is Associated With an Increased Risk of End‐Stage Renal Disease: A Population‐Based Cohort Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70845}
}
EUVIMED